GSK J1 is primarily used in research settings as a selective inhibitor of the histone demethylase enzymes KDM6A (UTX) and KDM6B (JMJD3). These enzymes are involved in the regulation of gene expression by removing methyl groups from histone proteins, which can influence chromatin structure and gene activity. By inhibiting these enzymes, GSK J1 helps scientists study the role of histone demethylation in various biological processes, including cell differentiation, immune response, and cancer development. Its application is particularly valuable in understanding the epigenetic mechanisms that control gene expression and in exploring potential therapeutic targets for diseases linked to abnormal histone methylation patterns.